JP2021511333A5 - - Google Patents

Info

Publication number
JP2021511333A5
JP2021511333A5 JP2020540253A JP2020540253A JP2021511333A5 JP 2021511333 A5 JP2021511333 A5 JP 2021511333A5 JP 2020540253 A JP2020540253 A JP 2020540253A JP 2020540253 A JP2020540253 A JP 2020540253A JP 2021511333 A5 JP2021511333 A5 JP 2021511333A5
Authority
JP
Japan
Prior art keywords
optionally substituted
antibody
antigen
binding fragment
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511333A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050446 external-priority patent/WO2019142147A2/en
Publication of JP2021511333A publication Critical patent/JP2021511333A/ja
Publication of JP2021511333A5 publication Critical patent/JP2021511333A5/ja
Pending legal-status Critical Current

Links

JP2020540253A 2018-01-18 2019-01-18 Ｃｄ１３４＋細胞の枯渇のための組成物および方法 Pending JP2021511333A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619106P 2018-01-18 2018-01-18
US62/619,106 2018-01-18
PCT/IB2019/050446 WO2019142147A2 (en) 2018-01-18 2019-01-18 Compositions and methods for the depletion of cd134+ cells

Publications (2)

Publication Number Publication Date
JP2021511333A JP2021511333A (ja) 2021-05-06
JP2021511333A5 true JP2021511333A5 (enExample) 2022-02-24

Family

ID=67300964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540253A Pending JP2021511333A (ja) 2018-01-18 2019-01-18 Ｃｄ１３４＋細胞の枯渇のための組成物および方法

Country Status (5)

Country Link
US (1) US20210101990A1 (enExample)
EP (1) EP3740233A4 (enExample)
JP (1) JP2021511333A (enExample)
CN (1) CN111867621A (enExample)
WO (1) WO2019142147A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732807A (zh) * 2022-03-27 2022-07-12 苏州大学 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
BRPI0811466A2 (pt) * 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
KR20110028450A (ko) * 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EA033468B1 (ru) * 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
JP2017531620A (ja) * 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
US9434785B1 (en) * 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
CN116726190A (zh) * 2015-06-20 2023-09-12 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates

Similar Documents

Publication Publication Date Title
JP2020506176A5 (enExample)
WO2023078273A1 (en) Specific conjugation for an antibody-drug conjugate
US10836796B2 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
CN110461876B (zh) 用于耗尽cd137+细胞的组合物和方法
US9988408B2 (en) Cytotoxic agents for conjugation to a cell binding molecule
CN105849086B (zh) 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
AU2012385228B2 (en) Conjugates of cell binding molecules with cytotoxic agents
CN106414465B (zh) 带电荷链接体及其在共轭反应上的应用
JP7458975B2 (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
KR102962848B1 (ko) 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도
CN108026123B (zh) 用于偶联的亲水链接体
RU2723651C2 (ru) Цитотоксические и антимитотические соединения и способы их применения
RU2432361C2 (ru) Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
JP2019522680A (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
TW201922782A (zh) 去除cd117+細胞之組合物及方法
BR112019012483A2 (pt) conjugados de fármaco de anticorpo para ablar células-tronco hematopoiéticas
JP2022529727A5 (enExample)
ES2702181T3 (es) Filtración con carbono activado para la purificación de ADC de benzodiazepina
JP2022535527A5 (enExample)
JP2023514347A5 (enExample)
JP2021517133A5 (enExample)
WO2019142147A2 (en) Compositions and methods for the depletion of cd134+ cells
NZ736728B2 (en) Cd123 antibodies and conjugates thereof
NZ615735A (en) Cd37-binding molecules and immunoconjugates thereof